Expression of epidermal growth factor (EGF) receptor by human breast cancer tissues has an inverse relationship with expression of the estrogen receptor and may be associated with a poor clinical response. We have studied the regulation of EGF receptor expression in a series of human breast cancer cell lines with varying degrees of estrogen responsiveness. Three estrogen receptor-positive lines, MCF-7, ZR-75-1, and T47D, were found to have less than 70,000 EGF binding sites per cell by radioreceptor assay and were growth stimulated in vitro by EGF. Four estrogen receptor-negative lines, MDA-MB-231, Hs578T, EVSA-T, and BT-20, contained greater than 70,000 EGF binding sites per cell and showed no in vitro growth stimulation by EGF. In all cell lines EGF receptor number was correlated with the amount of EGF receptor protein and RNA. Differences in EGF receptor expression between the cell types was not due to amplification of the EGF receptor gene. Rather, variations in EGF receptor expression between lines were due, at least in part, to differences in the rate of EGF gene transcription as determined by nuclear run-off studies. Our data confirm the previously described inverse relationship between expression of EGF and estrogen receptors. We show here that the absence of estrogen receptor expression in human breast cancer cell lines is associated with higher levels of functional EGF receptor protein and mRNA. (Molecular Endocrinology 1: 216-223, 1987) 
INTRODUCTION Epidermal growth factor (EGF) stimulates or inhibits the growth of a wide variety of benign and malignant cell lines in vitro (for review see Ref. 1). This response is elicited through binding of EGF or a related polypeptide,
0888-8809/87/0216-0223$02.00/0 Molecular Endocrinology Copyright © 1987 by The Endocrine Society such as transforming growth factor a to a 170,000 dalton glycoprotein receptor. This receptor consists of an extracellular EGF-binding domain linked by a transmembrane region to an intracellular component possessing tyrosine kinase activity (2) (3) (4) (5) . The EGF receptor shows extensive sequence homology to the avian erythroblastosis virus oncogene product, v-erbB, suggesting that the EGF receptor gene corresponds to the human c-erbB oncogene (6) . It has been proposed that amplification, rearrangement, or increased expression of the EGF receptor gene may be related to the neoplastic process in some types of human tumors. Several studies have demonstrated EGF receptor gene amplification in primary human tumors of glial origin (7) , in a number of human squamous cell carcinoma lines (8, 9) , and in a single breast carcinoma cell line (10) .
The role of the EGF receptor as a mediator of human breast cancer cell growth has only recently come under investigation whereas the role of steroid receptors has been studied for many years. Breast cancer in humans often possesses estrogen receptors (ER) and ER-positive tumors respond to hormonal therapy such as antiestrogens in about two-thirds of cases. ER-positive tumors are associated with a better prognosis than ERnegative tumors (11) . The ER-negative tumors usually have poorer histologic differentiation, a higher degree of nuclear atypia, and an increased thymidine labeling index in vitro (12) . In vitro, human breast cancer cells which are ER-positive manifest a growth stimulation upon treatment with estrogens (13) . Some human breast cancer cell lines such as MCF-7 and T47D, both ER-positive, also respond to EGF in vitro (14) (15) (16) . EGF receptors have been demonstrated in a variety of human breast cancer cell lines and fresh tumor specimens, and the presence of EGF receptor sites in breast tumors has been inversely correlated with the presence of estrogen receptor (17) (18) (19) . It has been suggested that the growth of some poor prognosis ER-negative breast tumors may be regulated by interaction of peptide growth factors like EGF with the EGF receptor (19) .
To further our understanding of the role of EGF and its receptor in breast cancer and their relationship with ER and tumor differentiation, we have studied the expression of the EGF receptor gene in a series of ERpositive and negative human breast cancer cell lines. Our goal was first to determine if these breast cancer cell lines demonstrated the same inverse relationship between level of ER and EGF receptor seen in primary tumors. Second, we wished to determine the level at which EGF receptor gene expression was regulated. Table 1 shows the ER and EGF receptor binding analysis for the cell lines under study. MCF-7, ZR-75-1, and T47D cells contained ER while Hs578T, MDA-MB-231, BT-20, and EVSA T cells lacked detectable ER. In contrast the four ER-negative cell lines had high EGF binding sites ranging from 90,000 to 257,000 sites per cell and the ER-positive cell lines contained a lower number of sites ranging from 2400 to 43,700 sites per cell. EGF receptor binding was also determined for A431 and KB squamous carcinoma cell lines and found to be 2,000,000 and 160,000 sites per cell, respectively. These values are similar to those reported previously (20) . The Kd of the high affinity binding sites for all cell lines was between 1 and 5 x 10~1 0 M. The effects of EGF on cell growth are shown in Table  2 . Treatment with 5 nM EGF for 4 days led to a 1.5-to 1.8-fold increase in cell number only in the three low EGF receptor, ER-positive cell lines, MCF-7, T47D, and ZR-75-1; EGF had no effect or an inhibitory effect on the growth rate of EGF receptor-rich ER-negative cell lines. Similar results were noted with EGF concentrations of up to 50 nM. Studies of the effects of low doses of EGF (0.5 pM to 0.5 nM) on the cell lines showed that concentrations of 0.5-5 pM EGF were mitogenic for Hs578T cells (1.5-fold over control). However, neither BT20 nor MDA-MB-231 cells were growth stimulated by any concentration of EGF tested. As a control the growth of A431 cells in the presence of 0.5 pM to 5 nM EGF was examined and a marked inhibition was seen at all concentrations except 0.5 pM which was slightly stimulatory (not shown). Thus, except at very low concentrations, the growth stimulatory effects of EGF are limited to those cells which possess relatively low numbers of EGF receptor.
RESULTS

EGF Binding and Effect on Growth of Breast Cancer Cell Lines
Immunoprecipitation of EGF Receptor Protein
To examine the amount of EGF receptor protein in representative cell lines, cells were labeled for 16 h with [ 35 S]methionine and cell lysates and media were immunoprecipitated with a monoclonal antibody to EGF receptor, R1. As shown in Fig. 1 , the 170 kilodalton EGF receptor protein was easily seen in A431 cells which were included as a positive control. Immunoprecipitable EGF receptor protein was detectable in MDA-MB-231 and Hs578T cells and present in small amounts in T47D cells. However, no immunoprecipitable p170 could be identified in MCF-7 or ZR-75-1 cells. Additionally a 93 kilodalton protein of unknown significance was immunoprecipitated in small amounts from A431, MDA-MB-231 , and Hs578T cells and was a major species in T47D cells. This protein may represent a previously described carboxyterminal truncated tryptic fragment of the EGF receptor of similar size (21) . A smaller 105 kilodalton protein representing the previously described carboxyterminus truncated receptor molecule was also found in the medium from A431 cells while no specific proteins were immunoprecipitated from the media of the breast cancer cell lines (not shown). 
-
Fig. 1. Immunoprecipitation of EGF Receptor from Cell Lines
Quantitative immunoprecipitation of EGF receptor was carried out after a 16-h metabolic labeling of cells using the EGF receptor antibody, R1 (lanes marked +) or a nonspecific antibody (lanes marked -) . A431, MDA-MB-231, Hs578T, and T47D cells were studied in one experiment while MCF-7 and ZR-75-1 cells were examined in a separate experiment. Size is in kilodaltons.
Expression of EGF Receptor RNA
To ascertain whether the amount of EGF receptor RNA was correlated with EGF receptor protein expression, the level of EGF receptor mRNA was measured using the cDNA clone, pE7, as a probe. Figure 2 shows a slot blot quantitation of the amount of EGF receptor mRNA in the cell lines. Expression of RNA in the cell lines paralleled protein expression. Thus, EGF receptor mRNA was readily detected in control A431 and KB cells as well as in the MDA-MB-231, Hs578T, and T47D cell lines. The expression in MCF-7 and ZR-75-1 cells was just at or below the level of detection by densitometric scanning. Because EGF receptor mRNA expression was beneath the level of detection by Northern analysis in the breast cancer cell lines, we performed S1 nuclease analysis of total cellular RNA from these cells. For these studies we used a 3'-Pst \-Bam HI subclone of pE7 which codes for an intracellular portion of the receptor protein. This probe, when labeled by primer extension in an M13 subclone, was protected from S1 nuclease digestion by total RNA obtained from positive control A431 cells and MDA-MB-231, Hs578T and T47D cells to yield the expected 141 base pair (bp) fragment ( Fig. 3 ). Neither MCF-7 nor ZR-75-1 cells showed RNA probe protection. This result not only validated the slot blot analysis but correlated well with the results of the receptor binding and immunoprecipitation studies as shown in Fig. 4 . Here the relative levels of receptor sites, immunoprecipitable EGF receptor protein, and EGF receptor mRNA were plotted for each cell line. The good correlation between these parameters for each cell line suggested to us that differences in EGF receptor RNA level may account at least in part for the variation in EGF receptor expression.
To determine whether EGF receptor expression is controlled at the transcriptional level, nuclear run-off Table 1 , Fig. 1, and Fig. 2 , respectively. Fig. 3 . S1 Analysis of EGF Receptor mRNA Using a pE7 Subclone S1 nuclease protection assays were performed as described in Materials and Methods. Total RNA from indicated cell lines (10 ^g) was hybridized to a radiolabeled pE7 subclone. The products of hybridization were digested with S1 nuclease and electrophoresed on an 8 M urea-5% polyacrylamide gel. Residual undigested probe is shown at 209 bp; lanes with 10 M9 tRNA or no RNA showed only this band on routine exposure (not shown). This autoradiograph was purposely overexposed to attempt to visualize hybridizing bands in MCF-7 and ZR-75-1 cells. Size is in base pairs. assays were performed with A431 cells and two selected breast cancer cell lines, MDA-MB-231 cells which had the highest expression of EGF receptor and MCF-7 cells which had the lowest level of EGF receptor expression amongst our cell lines. As shown in Table 3 we were unable to detect run-off transcripts for EGF receptor in MCF-7 cells. However, in the MDA-MB-231 and A431 cells (used as a positive control), EGF receptor transcripts were synthesized during run-off. The run-off probes gave no hybridization to pBR-322. When the run-off probes were hybridized to the actin cDNA clone, levels of actin transcription were relatively uniform, varying by no more than a factor of two between the cell lines tested. This confirms relative uniformity in transcript labeling of the different cell lines. Therefore, increased transcription rates may account at least in part for the increased level of EGF receptor expression in ER-negative breast cancer cells.
bp 141 bp
EGF Receptor Gene Analysis by Southern Hybridization
Since EGF receptor gene amplification has been found in some cancer cell lines and may account for enhanced Nuclei from each cell line were incubated with [ 32 P]UTP to allow elongation of nascent RNA transcripts. Radiolabeled RNA was isolated from each line and equal numbers of counts were hybridized to nitrocellulose filters containing 1 ng pBR322, pE7 (cDNA clone for EGF receptor), or LK220 (cDNA for human actin gene). Results are expressed as mean arbitrary OD units ± SEM taken from densitometric scanning of autoradiograms exposed for 7 days. Each number includes results of triplicate determinations from a single experiment; a second experiment gave similar results. levels of EGF receptor expression, we performed Southern analysis on DNA from the cell lines to ascertain the copy number of the EGF receptor gene in the breast cancer cell lines. As shown in Fig. 5 , no evidence of gene amplification was seen in H/ndlll-digested DNA from MDA-MB-231, Hs578T, BT-20, T47D, MCF-7, or ZR-75-1 cells when compared with DNA from KB cells which are known not to be amplified for the EGF receptor gene. By contrast DNA from A431 cells showed the previously described amplification. Similar results were obtained with BamH\ and EcoRI digests (data not shown).
DISCUSSION
In this study permanent human breast cancer cell lines provided an in vitro model for the study of EGF receptor in breast cancer. All breast cancer cell lines examined possessed EGF receptor, a finding consistent with that of Fitzpatrick et al. (14) who noted the absence of EGF receptor in only one of 14 breast cancer cell lines studied; that cell line, DU-4475, grew in suspension while all other cell lines examined in that study and ours grew in monolayer. The number of EGF receptor binding sites per cell varied widely in our study as in Fitzpatrick's. However, in our study we demonstrated that the presence of a relatively low number of EGF receptors (<70,000 per cell) was associated with the ability of the cell to manifest a mitogenic response to EGF while cells with higher receptor numbers (>70,000 per cell) failed to respond as did the nonbreast cancer cell lines with high EGF receptor levels, KB and A431. Thus MCF-7, T47D, and ZR-75-1 cells demonstrated at least a 50% increase in cell number over control after 4 days of EGF treatment; in contrast, the EVSA-T, BT20, Hs578T, and MDA-MB-231 cell lines all showed a trend toward growth inhibition which was significant for Hs578T cells. The ability of MCF-7 and T47D cells and the inability of MDA-MB-231 cells to respond to similar concentrations of EGF has been reported previously (14) . However, Fitzpatrick et al. (14) noted a lack of growth stimulation in ZR-75-1 cells as well; variation in cell lines between laboratories may account for this difference. The inverse relationship between EGF receptor number and EGF-induced mitogenesis is not well understood although it has been demonstrated in A431 cells (22) and in other squamous carcinoma cell lines (23) as well as in a breast cancer cell line MDA-MB-468 (10), which possesses nearly 2 x 10 6 EGF binding sites per cell.
Expression of EGF receptor may be controlled by several mechanisms in the cell. Amplification of the EGF receptor gene has been observed in some glioblastomas (7) and in several cell lines established from squamous cell tumors (8, 9) . However, it is apparently an uncommon phenomenon in breast cancer. Only one breast cancer cell line has been reported to be geneamplified for EGF receptor, MDA-MB-468 (10) . None of our cell lines demonstrated gene amplification for the EGF receptor. Our study shows that the number of EGF binding sites and the amount of immunoprecipitable receptor protein and mRNA are directly related, suggesting that control is more frequently achieved at the level of transcriptional or immediate posttranscriptional events. Nuclear run-off studies comparing tran-scription of MCF-7 cells as an example of cells with low EGF receptor and MDA-MB-231 cells as representative of cells with high EGF receptor showed that the control is achieved at least in part at the step of RNA transcription. In contrast, Clark et al. (24) showed that EGF modulates EGF receptor gene expression at the posttranscriptional level.
Finally three recent studies (17) (18) (19) have provided evidence for a significant inverse relationship between the presence of EGF receptor as measured by displacement binding studies and/or immunohistochemical techniques and ER in breast cancer tissue specimens. One group (19) also noted that EGF receptors were found in a greater proportion of lymph node metastases (10/14) than primary tumors (35/104) suggesting that the presence of EGF receptor may be associated with metastatic potential. In view of its association with ER negativity, it may also be postulated that the presence of EGF receptor is related to overall state of tumor differentiation since absence of ER is highly associated with poor histological differentiation in breast cancer. Indirect evidence for this hypothesis may be drawn from a study of EGF receptor in human bladder cancer which showed that more invasive (21/24) than superficial (7/24) and more poorly differentiated (18/21) than moderately differentiated (10/27) tumors were positive for EGF receptor by immunohistochemical techniques (25) . Our findings with seven permanent breast cancer cell lines in vitro support these in vivo observations. Three of four ER negative breast cancer cell lines form tumors in the nude mouse and all possess relatively high numbers of EGF receptor (>70,000 per cell). In contrast all three ER positive breast cancer lines, MCF-7, ZR-75-1, and T47D demonstrate relatively few EGF receptors and all are tumorigenic in the oophorectomized nude mouse only in the presence of exogenous estrogens (26) .
The nature of the interaction, if any, between the estrogen and EGF receptors and their respective ligands in modulating breast cancer growth remains unclear. It is conceivable that overexpression of the EGF receptor may in some way directly downmodulate the estrogen receptor. It is also possible that expression of the estrogen receptor may interface with expression of the EGF receptor. Gene transfer studies should address these possibilities in the future. The cell lines described in this study may thus provide a convenient model system for study of the role of both steroid hormones and peptide growth factors like EGF and TGF-a in the genesis and maintenance of breast cancer.
MATERIALS AND METHODS
Cell Lines and Culture
The MCF-7 breast adenocarcinoma cells were obtained from Dr. Marvin Rich of the Michigan Cancer Foundation. The ZR-75-1 cell line was established at the National Cancer Institute and later cloned in our laboratory; EVSA-T cells were established in our laboratory. The MDA-MB-231, T47D, and BT-20 cell lines were obtained from the American Type Culture Association (Rockville, MD). The Hs578T cell line, the only carcinosarcoma in the study, was a gift from Dr. Adeline Hackett, Peralta Cancer Research Institute (Oakland, CA). A431 (vulvar carcinoma) and KB (originally isolated as an oral carcinoma) cells were obtained from Dr. Ira Pastan, National Cancer Institute. All cells were grown in improved and modified essential medium (IMEM) supplemented with glutamine (0.6 g/liter), gentamycin (40 mg/liter), and 5% fetal calf serum. Cultures were grown at 37 C in 5% CO2.
Cell Growth Experiments
Cells were plated in triplicate 12-mm wells under culture conditions described above. A431, KB, MDA-MB-231, Hs578T, and BT-20 cells were plated at 20,000 cells per well while ZR-75-1 , MCF-7, T47D and EVSA-T cells were plated at 30,000 cells per well. After 12 h, the medium was replaced with IMEM without serum in the absence or presence of 5nwi EGF. The cell number was determined after 4 days of culture.
EGF and ER Studies
For EGF receptor determination cells were plated in replicate 12-mm wells one day before the experiment. EGF-binding assays were carried out at 4 C as previously described (27) . Data were analyzed by Scatchard analysis (28) and expressed as K<j of high affinity receptors and as total receptors per cell. For these studies human EGF was obtained from Amgen (Thousand Oaks, CA) and iodinated by chloramine-T (29) .
ERs were analyzed as previously described by whole cell binding assays in replicate 12-mm wells after 30-min incubation at 37 C (13). Data were analyzed by Scatchard analysis (28) .
Immunoprecipitation Studies
Quantitative immunoprecipitation of EGF receptor was carried out after a 16-h metabolic labeling of cells as previously described (30) . Cell extracts were immunoprecipitated with 2 ng monoclonal antibody, R1, which was the gift of Dr. Michael Waterfield and Dr. Paul Bennett (ICRF Laboratories, London, UK) (21) . Gel electrophoresis, salicylate fluorography, and autoradiography were carried out as previously described (30) .
Isolation and Analysis of DNA and RNA
DNA and RNA were extracted from cells by guanidium isothiocyanate solubilization and cesium chloride density gradient centrifugation (31) . For Southern blots, 15 /xg DNA were digested with EcoRI, H/ndlll, or SamHI, electrophoresed in 0.9% agarose gels, and transferred to nitrocellulose (32) . For RNA slot blots 10 ng total RNA was denatured in formaldehyde and serially diluted onto a nitrocellulose membrane (33) . For preparation of RNA filters 5 ^g denatured polyadenylated RNA was fractionated on 1.1% agarose gels containing 2.2 M formaldehyde and transferred to a nitrocellulose membrane (34) .
The cDNA clone, pE7, encoding 2.4 kilobases of the human EGF receptor, was the gift of Drs. Glenn Merlino and Ira Pastan, National Cancer Institute (20) . Filters were hybridized to nick-translated pE7 insert in 50% formamide, 3x Denhardts, 3x SSC (1x SSC is 0.15 M NaCI-0.0015 M sodium citrate), 0.5% sodium dodecyl sulfate, 50 ng/m\ salmon sperm DNA, and 10% dextran sulfate at 37 C for 16 h, and washed twice in 0.5x SSC-0.25% sodium dodecyl sulfate and once in 0.1 x SSC at 60 C. Washed filters were exposed to Kodak XAR-5 film at -7 0 C. The amount of hybridization was quantified by densitometric scanning of autoradiographs. To ensure that equal amounts of RNA were loaded, RNA blots were stripped of probe and rehybridized to LK-220, a cDNA clone of the human actin gene (35) (a gift from Dr. L. Kedes, Stanford University, Palo Alto, CA), and RNA and DNA gels were visualized by ethidium bromide staining before transfer. Vol. 1 No. 3 S1 Nuclease Protection Assay S1 nuclease protection assays of labeled DNA probe hybridized to RNA were performed as described by Battey et al. (36) . The probe used, a gift of Dr. Edward Sausville, National Cancer Institute, was a 141 bp Pstl-fiamHI fragment of pE7 incorporating nucleotides 1618-1759 of the intracellular tyrosine kinase domain which was subcloned into M13. It was labeled with [ 32 P]dATP by primer extension of the M13 subclone, separated by preparative gel electrophoresis, and electroeluted to obtain a single-stranded probe including primer and polylinker sequences.
Nuclear Run-Off Transcription Assay
Nuclei were isolated from cells and transcription reactions were carried out as previously described (37) except that 500 /xCi [^PJUTP were used in each reaction mixture. The 32 Plabeled RNA was isolated by centrifugation through guanidium isothiocyanate-cesium chloride. For hybridization DNA was denatured by incubation with 0.2 M NaOH for 30 min at 25 C followed by neutralization with 10 vol 6x SSC. Triplicate aliquots of 1 ng DNA were immobilized on slot blots and hybridized with denatured ^P-labeled RNA for 3 days at 42 C. The same quantity of radioactivity was used for each hybridization. After hybridization filters were washed twice with 1 x SSC-0.5% sodium dodecyl sulfate for 1 h at 60 C and once with 1 x SSC and subjected to autoradiography.
